Background:
Breast cancer patients have a lifelong 2-4-fold increased risk of developing a second primary
tumor in the contralateral breast compared with the risk for a first primary
breast cancer in the general female population. Prevention of contralateral
breast cancer (CBC) has received increased attention during recent decades. Here, we summarize and discuss the available literature on drug preventive
therapy and CBC.Results: The endocrine-targetting drugs,
tamoxifen and
aromatase inhibitors are used as standard adjuvant treatment for
estrogen receptor (ER)-positive
breast cancer. Both are associated with relative risk reductions of CBC of up to 50%, but incur serious side effects. Several
prescription drugs originally developed for other purposes, including
bisphosphonates,
statins, non-steroidal anti-inflammatory drugs,
metformin,
anti-hypertensives and
retinoids, have shown anti-
cancer activity in preclinical models. However, results of observational studies on CBC are sparse and inconsistent, with only
statins demonstrating promise as preventive agents and a potential treatment option for ER-negative
breast cancer patients.Conclusion: Future studies are needed to assess the effect of
statins in risk reduction and to identify other drugs with chemopreventive potential against CBC. Eventually, efforts must be directed towards identifying those
breast cancer patients likely to benefit most from specific preventive
therapies.